BioSpace News Archive

Drug Development

Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial

Sound Pharmaceuticals is pleased to announce the completion of study enrollment in its Phase 2b clinical trial involving Meniere’s Disease.

March 6, 2019
·
2 min read
Business

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018

China Biologic Products Holdings, Inc. a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2018.

March 6, 2019
·
37 min read
Deals

Hill-Rom Raises Quarterly Dividend payable on March 29, 2019

Hill-Rom Holdings, Inc., announced that its board of directors declared a 5 percent increase in the company’s quarterly dividend rate, from the previous rate of $0.20 per share to $0.21 per share.

March 6, 2019
·
1 min read
Business

Zymeworks Reports 2018 Year-End Financial Results

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, reported financial results for the year ended December 31, 2018.

March 6, 2019
·
11 min read
Pharm Country

Bristol-Myers Squibb to Take Part in the Barclays 2019 Global Healthcare Conference

Bristol-Myers Squibb Company will take part in a fireside chat at the Barclays 2019 Global Healthcare Conference on Wednesday, March 13, 2019, in Miami.

March 6, 2019
·
1 min read
Biotech Bay

Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women

Gilead Sciences, Inc. announced 48-week results from a Phase 2/3 study evaluating the efficacy and safety of Biktarvy®, a once-daily single tablet regimen, in virologically suppressed adolescents and children at least 6 years of age who are living with HIV.

March 6, 2019
·
10 min read
Biotech Bay

Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance

Gilead Sciences, Inc. announced data from two studies evaluating the resistance profile of Biktarvy® in virologically suppressed adults switching from dolutegravir/abacavir/lamivudine or a boosted protease inhibitor-based regimen for the treatment of HIV-1.

March 6, 2019
·
9 min read
BioMidwest

Market Scope Reports Global Demand for Spine Surgery Grows With Access to Care

Global demand for spine surgery is expected to rise at a compound annual growth rate of 9.7 percent from 2018 to 2023, with annual volume increasing from 3.6 million to 4.3 million procedures.

March 6, 2019
·
2 min read
Biotech Beach

Nex Cubed Selects Seven Transformative Frontier Tech Companies for Spring 2019 Digital Health Accelerator

Nex Cubed has announced seven companies selected to participate in its Spring 2019 Digital Health Accelerator.

March 6, 2019
·
6 min read
Biotech Bay

HelloMD Extends HIPAA Compliant Video Chats, Between Cannabis Patients and Doctors, to all 50 States

Having connected more than 100,000 cannabis patients to doctors and nurse practitioners in California, New York, and Canada via online video, HelloMD now says “Hello!” to canna-curious patients nationwide.

March 6, 2019
·
3 min read